MEIPMEI Pharma, Inc.

Nasdaq meipharma.com


$ 3.08 $ -0.12 (-3.75 %)    

Tuesday, 07-May-2024 10:05:14 EDT
QQQ $ 441.73 $ 2.16 (0.49 %)
DIA $ 389.24 $ 0.06 (0.02 %)
SPY $ 518.43 $ 0.87 (0.17 %)
TLT $ 90.88 $ 0.03 (0.03 %)
GLD $ 214.10 $ -0.42 (-0.2 %)
$ 3.2
$ 3.08
$ 0.00 x 0
$ 0.00 x 0
$ 3.08 - $ 3.08
$ 3.01 - $ 6.91
15,179
na
21.32M
$ 1.08
$ 1.07
TBD
na
na ($ 0.55)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-13-2024 12-31-2023 10-Q
2 11-09-2023 09-30-2023 10-Q
3 09-26-2023 06-30-2023 10-K
4 05-11-2023 03-31-2023 10-Q
5 02-09-2023 12-31-2022 10-Q
6 11-14-2022 09-30-2022 10-Q
7 09-08-2022 06-30-2022 10-K
8 05-23-2022 03-31-2022 10-Q
9 02-10-2022 12-31-2021 10-Q
10 11-10-2021 09-30-2021 10-Q
11 09-02-2021 06-30-2021 10-K
12 05-06-2021 03-31-2021 10-Q
13 02-04-2021 12-31-2020 10-Q
14 11-10-2020 09-30-2020 10-Q
15 09-09-2020 06-30-2020 10-K
16 05-07-2020 03-31-2020 10-Q
17 02-06-2020 12-31-2019 10-Q
18 11-07-2019 09-30-2019 10-Q
19 08-28-2019 06-30-2019 10-K
20 05-09-2019 03-31-2019 10-Q
21 02-07-2019 12-31-2018 10-Q
22 11-08-2018 09-30-2018 10-Q
23 08-30-2018 06-30-2018 10-K
24 05-09-2018 03-31-2018 10-Q
25 02-08-2018 12-31-2017 10-Q
26 11-08-2017 09-30-2017 10-Q
27 09-05-2017 06-30-2017 10-K
28 05-04-2017 03-31-2017 10-Q
29 02-08-2017 12-31-2016 10-Q
30 11-09-2016 09-30-2016 10-Q
31 09-06-2016 06-30-2016 10-K
32 05-05-2016 03-31-2016 10-Q
33 02-05-2016 12-31-2015 10-Q
34 11-06-2015 09-30-2015 10-Q
35 09-02-2015 06-30-2015 10-K
36 05-07-2015 03-31-2015 10-Q
37 02-06-2015 12-31-2014 10-Q
38 11-06-2014 09-30-2014 10-Q
39 09-09-2014 06-30-2014 10-K
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-hold-on-mei-pharma-maintains-7-price-target

Stifel analyst Stephen Willey maintains MEI Pharma (NASDAQ:MEIP) with a Hold and maintains $7 price target.

 mei-pharma-aligns-on-strategy-to-advance-voruciclib-and-me-344

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023...

 mei-pharma-reports-initial-data-from-clinical-study-evaluating-me-344-in-combination-with-bevacizumab-in-relapsed-metastatic-colorectal-cancer-patients

– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study –– ME-344 in Combination with Bevacizu...

 mei-pharma-q2-2024-gaap-eps-166-misses-132-estimate

MEI Pharma (NASDAQ:MEIP) reported quarterly losses of $(1.66) per share which missed the analyst consensus estimate of $(1.32) ...

 mei-pharma-filed-us-patent-application-20240016781-treatment-of-kras-mutant-cancers

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240016781

 mei-pharma-reports-clinical-data-on-oral-cdk9-inhibitor-voruciclib-at-ash2023

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity –– Initial...

 correction-mei-pharma-q1-eps-846-beats-212-estimate-sales-6530m-up-from-873m-yoy

MEI Pharma (NASDAQ:MEIP) reported quarterly earnings of $8.46 per share which beat the analyst consensus estimate of $(2.12) by...

 mei-pharma-q1-eps-846-beats-212-estimate-sales-6530m-up-from-873m-yoy

MEI Pharma (NASDAQ: MEIP) reported quarterly earnings of $8.46 per share which beat the analyst consensus estimate of $(2.12) b...

 mei-pharma-declares-special-cash-dividend-of-175-per-share-of-common-stock

The special cash dividen is payable on December 6, 2023 to stockholders of record at the close of business on November 17, 2023.

 mei-pharma-says-board-approved-adoption-of-limited-duration-stockholder-rights-plan-responds-to-substantial-stock-accumulation-by-anson-advisors-and-cable-car-capital

The Board of Directors resolved to adopt the Rights Plan following the recent Schedule 13D amendments filed by Anson Advisors a...

 stifel-maintains-hold-on-mei-pharma-lowers-price-target-to-9

Stifel analyst Stephen Willey maintains MEI Pharma (NASDAQ:MEIP) with a Hold and lowers the price target from $10 to $9.

 mei-pharma-q4-adj-eps-151-sales-146m-beat-93000k-estimate

MEI Pharma (NASDAQ:MEIP) reported quarterly adj. losses of $(1.51) per share. The company reported quarterly sales of $1.46 mil...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION